191 related articles for article (PubMed ID: 19485755)
1. Moving forward: a mucosal vaccine against group A streptococcus.
Georgousakis MM; McMillan DJ; Batzloff MR; Sriprakash KS
Expert Rev Vaccines; 2009 Jun; 8(6):747-60. PubMed ID: 19485755
[TBL] [Abstract][Full Text] [Related]
2. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
3. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
4. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
5. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.
Schulze K; Medina E; Guzmán CA
Vaccine; 2006 Feb; 24(9):1446-50. PubMed ID: 16289766
[TBL] [Abstract][Full Text] [Related]
6. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.
Bi S; Xu M; Zhou Y; Xing X; Shen A; Wang B
mBio; 2019 Nov; 10(6):. PubMed ID: 31772056
[TBL] [Abstract][Full Text] [Related]
7. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus.
Batzloff MR; Yan H; Davies MR; Hartas J; Lowell GH; White G; Burt DS; Leanderson T; Good MF
J Infect Dis; 2005 Oct; 192(8):1450-5. PubMed ID: 16170764
[TBL] [Abstract][Full Text] [Related]
8. Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus.
Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
Acta Biomater; 2016 Sep; 41():161-8. PubMed ID: 27063491
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
[TBL] [Abstract][Full Text] [Related]
10. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
Mannam P; Jones KF; Geller BL
Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
[TBL] [Abstract][Full Text] [Related]
11. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
[TBL] [Abstract][Full Text] [Related]
12. Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.
Mortensen R; Christensen D; Hansen LB; Christensen JP; Andersen P; Dietrich J
PLoS One; 2017; 12(4):e0175707. PubMed ID: 28414746
[TBL] [Abstract][Full Text] [Related]
13. A vaccine against S. pyogenes: design and experimental immune response.
Guilherme L; Postol E; Freschi de Barros S; Higa F; Alencar R; Lastre M; Zayas C; Puschel CR; Silva WR; Sa-Rocha LC; Sa-Rocha VM; Pérez O; Kalil J
Methods; 2009 Dec; 49(4):316-21. PubMed ID: 19409999
[TBL] [Abstract][Full Text] [Related]
14. Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice.
Dunn LA; McMillan DJ; Batzloff M; Zeng W; Jackson DC; Upcroft JA; Upcroft P; Olive C
Vaccine; 2002 Jun; 20(21-22):2635-40. PubMed ID: 12034087
[TBL] [Abstract][Full Text] [Related]
15. Mucosal and systemic immunization with targeted fusion anti-caries DNA plasmid in young rats.
Liu GX; Xu QA; Jin J; Li YH; Jia R; Guo JH; Fan MW
Vaccine; 2009 May; 27(22):2940-7. PubMed ID: 19428904
[TBL] [Abstract][Full Text] [Related]
16. Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation.
Moyle PM; Olive C; Ho MF; Burgess M; Karpati L; Good MF; Toth I
J Org Chem; 2006 Sep; 71(18):6846-50. PubMed ID: 16930036
[TBL] [Abstract][Full Text] [Related]
17. Systemic immunization with streptococcal immunoglobulin-binding protein Sib 35 induces protective immunity against group: a Streptococcus challenge in mice.
Okamoto S; Tamura Y; Terao Y; Hamada S; Kawabata S
Vaccine; 2005 Sep; 23(40):4852-9. PubMed ID: 15990202
[TBL] [Abstract][Full Text] [Related]
18. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
[TBL] [Abstract][Full Text] [Related]
19. Mucosal immunization using recombinant plant-based oral vaccines.
Streatfield SJ
Methods; 2006 Feb; 38(2):150-7. PubMed ID: 16431131
[TBL] [Abstract][Full Text] [Related]
20. Group A streptococcal vaccines: facts versus fantasy.
Steer AC; Batzloff MR; Mulholland K; Carapetis JR
Curr Opin Infect Dis; 2009 Dec; 22(6):544-52. PubMed ID: 19797947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]